-
Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, Grilnberger E, Laferl H, Dienes HP, Popow-Kraupp T, Ferenci P, Holzmann H, 2006: Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection[J]. J Clin Virol, 36, 24-31. doi: 10.1016/j.jcv.2005.12.010
-
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS, 1994: The prevalence of hepatitis C virus infection in the United States, 1988 through[J]. N Engl J Med, 341, 556-562.
-
Botros M, Sikaris KA, 2013: The De Ritis ratio: the test of time[J]. Clin Biochem Rev, 34, 117-130.
-
Chassagne F, Rojas Rojas T, Bertani S, Bourdy G, Eav S, Ruiz E, Pineau P, Deharo E, 2016: A 13-year retrospective study on primary liver cancer in cambodia: a strikingly high hepatitis C occurrence among hepatocellular carcinoma cases[J]. Oncology, 91, 106-116. doi: 10.1159/000446398
-
Craxì A, Cammà C, 2005: Prevention of hepatocellular carcinoma[J]. Clin Liver Dis, 9, 329-346. doi: 10.1016/j.cld.2004.12.008
-
De Ritis F, Coltorti M, Giusti G, 2006: An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities[J]. Clin Chim Acta, 369, 148-152. doi: 10.1016/j.cca.2006.05.001
-
Durante-Mangoni E, Vallefuoco L, Sorrentino R, Iossa D, Perna E, Molaro R, Braschi U, Zampino R, Sodano G, Adinolfi LE, Utili R, Portella G, 2013: Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection[J]. J Med Virol, 85, 1913-1918. doi: 10.1002/jmv.23672
-
El-Serag HB, Mason AC, 1999: Rising incidence of hepatocellular carcinoma in the United States[J]. N Engl J Med, 340, 745-750. doi: 10.1056/NEJM199903113401001
-
Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, O'Connell J, Collins JK, Shanahan F, 1999: Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population[J]. Hepatol Baltim Md, 29, 904-907. doi: 10.1002/(ISSN)1527-3350
-
Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S, 2011: JPHC Study Group. Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: a population-based cohort study (JPHC Study)[J]. Cancer Lett, 300, 173-179. doi: 10.1016/j.canlet.2010.10.002
-
Jutavijittum P, Yousukh A, Samountry B, Samountry K, Ounavong A, Thammavong T, Keokhamphue J, Toriyama K, 2007: Seroprevalence of hepatitis B and C virus infections among Lao blood donors[J]. Southeast Asian J Trop Med Public Health, 38, 674-679.
-
Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VWS, Wong GL-H, Nguyen MH, 2017: HCV genotype 6 increased the risk for hepatocellular carcinoma among Asian patients with liver cirrhosis[J]. Am J Gastroenterol, 112, 1111-1119. doi: 10.1038/ajg.2017.123
-
Lim SG, Aghemo A, Chen P-J, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K, 2017: Management of hepatitis C virus infection in the Asia-Pacific region: an update[J]. Lancet Gastroenterol Hepatol, 2, 52-62. doi: 10.1016/S2468-1253(16)30080-2
-
Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY, 2015: The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection[J]. Ann Intern Med, 162, 619-629. doi: 10.7326/M14-1313
-
Mahajan R, Midha V, Goyal O, Mehta V, Narang V, Kaur K, Singh A, Singh D, Bhanot R, Sood A, 2017: Clinical profile of hepatitis C virus infection in a developing country-India[J]. J Gastroenterol Hepatol, 33, 926-933.
-
Malyĭ VP, Pen'kov DV, Chiriukina OI, 2013: Cycloferon therapy of acute and chronic virus hepatitis C[J]. Antibiot Khimioter Antibiot Chemoter Sic, 58, 34-40.
-
Noh R, Lee DH, Kwon BW, Kim YH, Kim SB, Song IH, 2016: Clinical impact of viral load on the development of hepatocellular carcinoma and liver-related mortality in patients with hepatitis c virus infection[J]. Gastroenterol Res Pract, 2016, 7476231-.
-
Paboriboune P, Vial T, Chassagne F, Sitbounlang P, Soundala S, Bertani S, Sengmanothong D, Babin F-X, Steenkeste N, Dény P, Pineau P, Deharo E (2018) A seven-year retrospective study on the surveillance of hepatitis B in Laos. Int J Hepatol. https://doi.org/10.1155/2018/9462475
-
Romantsov MG, Kovalenko SN, Sologub TV, Anikina OV, 2008: Immunomodulators in the 'gold standard' of the chronic viral hepatitis C therapy[J]. Antibiot Khimioter, 53, 18-22.
-
Romantsov MG, Kremen' NV, Sologub TV, 2010: Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach[J]. Eksp Klin Farmakol, 73, 14-17.
-
Smith J, Aberle JH, Fleming VM, Ferenci P, Thomson EC, Karayiannis P, McLean AR, Holzmann H, Klenerman P, 2010: Dynamic coinfection with multiple viral subtypes in acute hepatitis C[J]. J Infect Dis, 202, 1770-1779. doi: 10.1086/653024
-
Sologub TV, Romantsev MG, Shul'diakov AA, Lin'kova IN, Radchenko VG, Kovalenko AL, 2010: Efficiency of using cycloferon as part of combined therapy for chronic hepatitis C (a review of multicenter clinical trials)[J]. Ter Arkh, 82, 78-81.
-
Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM, Loukas A, 2012: The tumorigenic liver fluke Opisthorchis viverrini—multiple pathways to cancer[J]. Trends Parasitol, 28, 395-407. doi: 10.1016/j.pt.2012.07.006
-
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, 2016: The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013[J]. Lancet, 388, 1081-1088. doi: 10.1016/S0140-6736(16)30579-7
-
Su WP, Peng CY, Lai HC, Liao KF, Huang WH, Chuang PH, Chen CB, Jeng LB, 2009: Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy[J]. Hepatogastroenterology, 56, 798-801.
-
Voronkova NV, Blokhina NP, Kelli EI, Mikhaĭlov MI, Malyshev NA, 2002: Prospects for interferon therapy in chronic hepatitis C with normal transaminase levels[J]. Ter Arkh, 74, 12-15.
-
WHO (2014) Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164_apr2014/en/. Accessed 20 April 2018
-
WHO (2016) Model lists of essential medicines. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 20 April 2018
-
WHO (2017) Towards access 2030. http://www.who.int/medicines/publications/towards_access2030/en/. Accessed 20 April 2018